GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New weapon against aggressive esophageal cancer shows promise
Disease control CompletedThis completed Phase 3 trial tested whether adding the targeted drug trastuzumab to standard treatment improves outcomes for people with a specific type of esophageal cancer (HER2-positive). The standard treatment involved chemotherapy, radiation, and surgery. Researchers wanted …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 20:11 UTC
-
Gut bacteria joins fight against advanced cancer
Disease control CompletedThis early-stage study tested whether adding a new investigational therapy called VE800—a preparation of specific bacteria—could improve the effectiveness of an existing immunotherapy drug (nivolumab) in patients with advanced or metastatic cancers. The trial enrolled 56 patients…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Vedanta Biosciences, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Breakthrough trial tests immune drug combo against aggressive stomach cancers
Disease control CompletedThis large Phase 3 trial tested whether adding a new immune-boosting drug called AK104 to standard chemotherapy works better than chemotherapy alone for people with advanced stomach or gastroesophageal cancer. The study involved 610 adults who had not received prior treatment for…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New hope for tough stomach cancers: two drugs team up
Disease control CompletedThis study tested whether combining two drugs, TAS-102 and ramucirumab, is safe and can help people with advanced stomach or gastroesophageal cancer that has stopped responding to other treatments. It involved 23 patients to see if the combination could help them live longer and …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Major cancer trial tests new weapon against aggressive stomach tumors
Disease control CompletedThis large, completed Phase 3 trial tested whether adding the immunotherapy drug pembrolizumab to the standard first-line treatment (trastuzumab plus chemotherapy) could better control advanced HER2-positive stomach or gastroesophageal junction cancer. It involved 738 participant…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
First safety test of new cancer drug for chinese patients
Disease control CompletedThis study tested the safety and how the body processes an experimental drug called SGN-B6A in Chinese patients with advanced solid tumors. It involved a small group of 6 participants who had cancers like lung, head and neck, or stomach cancer that had stopped responding to stand…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New drug combo tested for Tough-to-Treat stomach cancers
Disease control CompletedThis study tested whether a new drug called GEN-001, when combined with an existing immunotherapy (avelumab), could help control advanced stomach or gastroesophageal junction cancer. It was for patients whose cancer had progressed after at least two prior standard treatments and …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Genome & Company • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
First human trial tests new weapon against multiple cancers
Disease control CompletedThis early-stage study aimed to find a safe and effective dose of a new drug called TPST-1495, given alone or with an existing immunotherapy (pembrolizumab), for people with advanced solid tumors. It enrolled 89 adults with cancers like colorectal, lung, and head and neck cancer …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Tempest Therapeutics • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC